14 results on '"Su TH"'
Search Results
2. Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective.
- Author
-
Su TH and Kao JH
- Published
- 2021
- Full Text
- View/download PDF
3. Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level.
- Author
-
Chen HS, Wu JF, Su TH, Chen HL, Hsu HY, Xia NS, Chen PJ, and Chang MH
- Subjects
- Adolescent, Child, Female, Follow-Up Studies, Humans, Male, Young Adult, Alanine Transaminase blood, Hepatitis B Antibodies blood, Hepatitis B Core Antigens immunology, Hepatitis B e Antigens blood, Hepatitis B, Chronic immunology, Seroconversion
- Abstract
It is not clear whether baseline hepatitis B core antibody (anti-HBc) level in hepatitis B e antigen (HBeAg)-positive children with a normal alanine aminotransferase (ALT) level is predictive of spontaneous HBeAg seroconversion. We investigated the correlation between anti-HBc level and the natural course of chronic hepatitis B (CHB) virus (HBV) infection in children, particularly the ability of baseline anti-HBc level to predict spontaneous HBeAg seroconversion during long-term follow-up. HBeAg-positive children with untreated CHB and a normal ALT level were followed longitudinally. Anti-HBc level was determined by double-sandwich immunoassay. Effects of anti-HBc levels and other parameters on spontaneous HBeAg seroconversion and the natural course of CHB were assessed. A total of 182 children (106 males) with a median age at enrollment of 10.6 years (interquartile range [IQR], 10.3-15.3) were followed for a median of 19.8 years (IQR, 11.9-21.9). Spontaneous HBeAg seroconversion occurred in 85 children (46.7%) during the follow-up. A baseline anti-HBc titer of >500 IU/mL (hazard ratio [HR] = 2.81), HBV genotype B and B + C (HR = 3.46), and a baseline hepatitis B surface antigen titer of ≤4.8 log
10 IU/mL (HR = 3.09) were predictive of spontaneous HBeAg seroconversion, based on multivariable survival analysis (P < 0.001). In cases remaining HBeAg positive, their anti-HBc levels increased gradually during follow-up because of ongoing inflammation. Conclusion: Baseline anti-HBc level is predictive of spontaneous HBeAg seroconversion in HBeAg-positive children with a normal ALT level. Anti-HBc level reflects anti-HBV immune response in the HBeAg-positive normal ALT phase of CHB., (© 2019 by the American Association for the Study of Liver Diseases.)- Published
- 2019
- Full Text
- View/download PDF
4. Letter to the Editor: Deliberations More Than a Cut-off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation.
- Author
-
Jeng WJ, Hsu YC, Su TH, and Chen CH
- Subjects
- Hepatitis B Surface Antigens, Hepatitis B e Antigens, Hepatitis B virus, Humans, Hepatitis B, Chronic
- Published
- 2019
- Full Text
- View/download PDF
5. Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma.
- Author
-
Liao SH, Su TH, Jeng YM, Liang PC, Chen DS, Chen CH, and Kao JH
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Liver Neoplasms mortality, Liver Neoplasms pathology
- Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Sarcomatoid HCC is a rare histological subtype of HCC with largely unclear clinical manifestations and outcomes. We evaluated the clinical manifestations and outcomes of patients with sarcomatoid HCC. We identified 5,047 patients with histologically proven HCC from the Cancer Registry Database (1996-2016) of National Taiwan University Hospital. Among them, 40 patients with sarcomatoid HCC were identified from the pathology database of National Taiwan University Hospital. We included 160 patients with nonsarcomatoid HCC through propensity score matching according to sex, age, and Barcelona Clinic Liver Cancer stage. The majority of these patients with sarcomatoid HCC were men (75%); their median age was 58 years. Only 47.5% of the patients with sarcomatoid HCC presented with typical image patterns of HCC. The pathological grading of sarcomatoid HCC was more advanced compared with that of nonsarcomatoid HCC (42.5% vs. 23.8% in grade III and IV, P < 0.0001). The sarcomatoid group had significantly shorter median recurrence-free (13.3 vs. 84.2 months, log-rank P < 0.0001) and overall (8.3 vs. 69.3 months, log-rank P < 0.0001) survival than did the nonsarcomatoid group. The results of the multivariable Cox proportional hazard model revealed histological sarcomatoid subtype as an independent factor for all-cause mortality (hazard ratio [HR], 6.47; 95% confidence interval [CI], 3.12-13.43; P < 0.0001) and tumor recurrence (HR, 4.08; 95% CI, 1.72-9.66; P = 0.001). Conclusion: Compared with nonsarcomatoid HCC, sarcomatoid HCC was associated with more advanced histological grades and atypical image patterns. Histological sarcomatoid subtype is an independent predictor of tumor recurrence after curative treatment and all-cause mortality in patients with HCC., (© 2018 by the American Association for the Study of Liver Diseases.)
- Published
- 2019
- Full Text
- View/download PDF
6. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.
- Author
-
Papatheodoridis GV, Manolakopoulos S, Su TH, Siakavellas S, Liu CJ, Kourikou A, Yang HC, and Kao JH
- Subjects
- Adult, DNA, Viral, Female, Follow-Up Studies, Hepatitis B e Antigens, Humans, Male, Middle Aged, Recurrence, Retreatment statistics & numerical data, Treatment Outcome, Withholding Treatment statistics & numerical data, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy
- Abstract
Relapses are observed in most hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear. The aim of this study was to assess the impact of different definitions on the rates of posttreatment relapse and therefore on the probability of retreatment in patients who have discontinued effective long-term NA therapy. In total, 130 HBeAg-negative chronic hepatitis B patients without cirrhosis and before NA treatment were included. All had on-therapy virological remission for ≥24 months and close follow-up for ≥12 months after stopping NA treatment or until retreatment, which started on stringent predefined criteria. Relapses rates based on several predetermined definitions of virological and perhaps biochemical criteria were assessed. The median duration of therapy was 60 months and the median duration of on-therapy virological remission was 43 months. During a median off-NAs follow-up of 15 months, no patient experienced liver decompensation or died. Cumulative relapse rates were 2%-49%, 4%-73%, 11%-82%, and 16%-90% at 3, 6, 12, and 24 months, respectively, whereas cumulative retreatment rates were 15%, 22%, and 40% at 6, 12, and 24 months, respectively, after discontinuation of NA therapy. No patient characteristic was independently associated with the probability of relapse based on at least two definitions or of retreatment., Conclusion: In HBeAg-negative chronic hepatitis B patients who discontinue NA therapy, the definition of relapse has a great impact on off-NAs relapse rates and potentially on the probability of retreatment. Regardless of definition, off-NAs relapses cannot be easily predicted by patient characteristics. A substantial proportion of such patients may not require retreatment if stringent criteria are adopted. (Hepatology 2017)., (© 2017 by the American Association for the Study of Liver Diseases.)
- Published
- 2018
- Full Text
- View/download PDF
7. HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?
- Author
-
Su TH, Tseng TC, and Kao JH
- Subjects
- Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis B virus, Humans, Liver Neoplasms, Treatment Outcome, Hepatitis B, Chronic, Liver Cirrhosis
- Published
- 2018
- Full Text
- View/download PDF
8. Reply.
- Author
-
Su TH, Chen CL, and Kao JH
- Published
- 2016
- Full Text
- View/download PDF
9. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study.
- Author
-
Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, and Kao JH
- Subjects
- Adult, Aged, Cohort Studies, Female, Hepatitis C complications, Hepatitis C drug therapy, Humans, Interferons therapeutic use, Lymphoma virology, Male, Middle Aged, Proportional Hazards Models, Taiwan epidemiology, Hepatitis C epidemiology, Lymphoma epidemiology
- Abstract
Unlabelled: Chronic hepatitis C viral (HCV) infection has been associated with non-Hodgkin's lymphoma (NHL); however, the results are inconsistent among regions with different HCV prevalence rates. The temporal relationship, risk estimates, and association between HCV and lymphoid-neoplasms remain unclear. This study investigated the temporal relationship between HCV infection and lymphoid-neoplasms using a nationwide population-based cohort. Patients with chronic HCV infection were retrieved from the Taiwan National Health Insurance Research Database during 2001-2005 and designated as the HCV cohort. Those with prior malignancies or coinfected with hepatitis B or human immunodeficiency virus were excluded. The age, sex, and comorbidities, including rheumatological disorders and diabetes, were matched by propensity scores to another non-HCV cohort. Both cohorts were followed longitudinally until 2009 for a new diagnosis of any lymphoid-neoplasms or NHL. A total of 11,679 HCV and 46,716 non-HCV patients were included and followed for 8 years. The incidence rates of any lymphoid-neoplasms and NHL were significantly greater in the HCV cohort than the non-HCV cohort (48.4 versus 22.1, and 37.0 versus 17.5 per 100,000 person-years, respectively, both P < 0.001), even after we excluded lymphoid-neoplasms developed within the first year of follow-up. Cox proportional hazards regression analysis (after adjustment for age, sex, numbers of annual medical visits during follow-up, and comorbidities) indicated that HCV infection was associated with an increased risk of either any lymphoid-neoplasms (hazard ratio = 2.30, 95% confidence interval 1.55-3.43, P < 0.0001) or NHL (hazard ratio = 2.00, 95% confidence interval 1.27-3.16, P = 0.003)., Conclusion: After adjustment for confounders and biases, chronic HCV infection is temporally associated with a two-fold increased risk of lymphoid-neoplasms, especially NHL, in Asian patients; additional large studies are needed to explore whether HCV eradication can reduce the incidence of lymphoid-neoplasms., (© 2015 by the American Association for the Study of Liver Diseases.)
- Published
- 2016
- Full Text
- View/download PDF
10. Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B.
- Author
-
Lin CL, Liu CH, Wang CC, Liang CC, Su TH, Liu CJ, and Kao JH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers blood, Biopsy methods, Female, Humans, Liver Cirrhosis blood, Liver Cirrhosis virology, Male, Middle Aged, Platelet Count, Retrospective Studies, Young Adult, Alanine Transaminase blood, Aspartate Aminotransferases blood, Hepatitis B, Chronic complications, Liver Cirrhosis diagnosis
- Abstract
Goals/background: Aspartate aminotransferase to platelet ratio index (APRI) and FIB-4 index are noninvasive biomarkers to evaluate hepatic fibrosis. However, their usefulness in chronic hepatitis B (CHB) patients remains unclear., Methods: A total of 631 CHB patients were enrolled and randomly divided into a training set (n=420) and a validation set (n=211). Areas under receiver operating characteristic (AUROC) curves for FIB-4 index and APRI were compared to evaluate their diagnostic values in identifying significant fibrosis and cirrhosis., Results: The AUROC of FIB-4 index for the diagnosis of significant fibrosis and cirrhosis in the entire cohort was higher than that of APRI (0.769 vs. 0.704, P=0.0003 and 0.869 vs. 0.706, P<0.0001). By using cutoff APRI of 0.38 and 4.04 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 67.7% and 76.8%. At cutoff FIB-4 index of 0.87 and 3.40 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 69.2% and 84.4%. Compared with patients with concordance, patients with overestimated score by FIB-4 index had a significantly higher serum alanine aminotransferase (ALT) level (299±245 vs. 168±196 U/L, P=0.001) as well as a higher ratio of hepatitis flare (ALT>400 U/L) (25% vs. 7.9%, P=0.008)., Conclusions: FIB-4 index proves to be more reliable than APRI in predicting significant fibrosis and cirrhosis in CHB patients. By using FIB-4 index, a substantial proportion of patients could be identified correctly as significant fibrosis and cirrhosis without further invasive liver biopsy.
- Published
- 2015
- Full Text
- View/download PDF
11. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
- Author
-
Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, and Kao JH
- Subjects
- Adult, Antiviral Agents therapeutic use, Drug Resistance, Viral genetics, Female, Hepatitis B e Antigens immunology, Hepatitis B virus immunology, Humans, Interferons therapeutic use, Male, Middle Aged, Multivariate Analysis, Polymerase Chain Reaction methods, Polymerase Chain Reaction standards, Predictive Value of Tests, Promoter Regions, Genetic genetics, Ribavirin therapeutic use, Sequence Analysis, DNA standards, Viral Load drug effects, Viral Load genetics, Young Adult, Drug Monitoring methods, Hepatitis B Antibodies blood, Hepatitis B e Antigens genetics, Hepatitis B virus genetics, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic immunology, Hepatitis B, Chronic virology, Sequence Analysis, DNA methods
- Abstract
Unlabelled: Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking. This study aimed to develop a new assay to accurately quantify the PC and BCP mutant percentages and correlate their dynamic changes with IFN-induced HBeAg seroconversion in HBeAg-positive CHB patients. The PC and BCP mutant percentages were analyzed by polymerase chain reaction (PCR)-pyrosequencing. Our results showed that this quantitative assay for PC and BCP mutants achieved high accuracy (R(2) > 0.99) within a range between 10% and 90% mutants. We examined dynamic changes of the PC and BCP mutant percentages following IFN treatment in 203 HBeAg-positive CHB patients. By multiple logistic regression analysis, we found that the chance of HBeAg seroconversion increased by 2.2% (odds ratio [OR] = 1.022, 95% confidence interval [CI]: 1.009-1.034, P = 0.001) and 2.3% (OR = 1.023, 95% CI: 1.010-1.037, P = 0.001) per 1% increase of the pretreatment PC and BCP mutant percentages, respectively, after adjustment for other predictors. However, only the pretreatment PC mutation percentage was significantly associated with HBeAg seroconversion with HBV DNA < 2,000 IU/mL (OR = 1.030, 95% CI: 1.014-1.047, P < 0.001). Furthermore, the mutant percentage of PC, but not BCP, in patients achieving HBeAg seroclearance with HBV DNA < 20,000 IU/mL increased significantly during IFN treatment (P = 0.039). Interestingly, patients with HBeAg seroconversion who had a high PC mutant percentage at the end of IFN treatment tended to exhibit high viremia after seroconversion., Conclusion: Quantitative analysis of PC and BCP mutants can predict IFN-induced HBeAg seroconversion and demonstrate their distinct evolution patterns during HBeAg seroconversion. (HEPATOLOGY 2013)., (Copyright © 2012 American Association for the Study of Liver Diseases.)
- Published
- 2013
- Full Text
- View/download PDF
12. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
- Author
-
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ, Chen DS, and Kao JH
- Subjects
- Adult, Alanine Transaminase blood, Disease Progression, Female, Hepatitis B, Chronic immunology, Hepatitis B, Chronic virology, Humans, Liver Cirrhosis etiology, Liver Cirrhosis virology, Male, Middle Aged, Taiwan epidemiology, Viral Load, DNA, Viral blood, Hepatitis B Surface Antigens blood, Hepatitis B virus genetics, Hepatitis B, Chronic physiopathology
- Abstract
Unlabelled: Chronic hepatitis B patients with high viral loads are at increased risk of cirrhosis and hepatocellular carcinoma (HCC). In patients with low viral loads, higher hepatitis B surface antigen (HBsAg) levels have been shown to predict HCC development. However, little is known about the difference in risk for other hepatitis B virus (HBV)-related adverse outcomes with varying HBsAg levels. A total of 1,068 Taiwanese hepatitis B e antigen (HBeAg)-negative HBV carriers with serum HBV DNA level <2,000 IU/mL at baseline were followed for a mean duration of 13.0 years. Patients were categorized based on their HBsAg levels, and the relationships between HBsAg level and development of HBeAg-negative hepatitis, hepatitis flare, and cirrhosis were investigated. Of the 1068 patients with low viral loads, 280 developed HBeAg-negative hepatitis, with an annual incidence rate of 2.0%. HBsAg level, but not HBV DNA level, was found to be a risk factor for HBeAg-negative hepatitis. Multivariate analysis showed that the adjusted hazard ratio in patients with an HBsAg level ≥ 1,000 versus <1000 IU/mL was 1.5 (95% confidence interval, 1.2-1.9). The positive correlation was present when evaluating other endpoints, including hepatitis flare and cirrhosis, and remained consistent when the study population was restricted to those with normal alanine aminotransferase (ALT) level at baseline. The annual incidence rate of HBeAg-negative hepatitis was lowered to 1.1% in patients with low levels of HBV DNA, HBsAg, and ALT., Conclusion: In HBeAg-negative patients with low viral loads and genotype B or C virus infection, a higher HBsAg level can predict disease progression. HBsAg <1,000 IU/mL in combination with low levels of HBV DNA and ALT help define minimal-risk HBV carriers., (Copyright © 2012 American Association for the Study of Liver Diseases.)
- Published
- 2013
- Full Text
- View/download PDF
13. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.
- Author
-
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, and Kao JH
- Subjects
- Adult, Biomarkers metabolism, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular virology, Cohort Studies, DNA, Viral metabolism, Female, Follow-Up Studies, Hepatitis B e Antigens genetics, Hepatitis B virus genetics, Hepatitis B virus growth & development, Hepatitis B, Chronic epidemiology, Humans, Incidence, Liver Cirrhosis diagnosis, Liver Cirrhosis epidemiology, Liver Cirrhosis virology, Liver Neoplasms diagnosis, Liver Neoplasms epidemiology, Liver Neoplasms virology, Male, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Recurrence, Viremia diagnosis, Viremia epidemiology, Viremia virology, Virus Replication physiology, Hepatitis B e Antigens metabolism, Hepatitis B virus isolation & purification, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic virology, Viral Load physiology
- Abstract
Unlabelled: Loss of hepatitis B surface antigen (HBsAg) usually indicates the cure of hepatitis B virus (HBV) infection. In spontaneous hepatitis B e antigen (HBeAg) seroconverters, lower serum HBsAg and HBV DNA levels have been shown to be associated with HBsAg loss over time. However, little is known about their impacts on HBsAg loss in HBeAg-negative patients with limited viral replication. A total of 688 HBeAg-negative patients with baseline serum HBV DNA levels <2000 IU/mL were enrolled in Taiwan. The relationships of HBsAg and HBV DNA levels with subsequent HBsAg loss were investigated. In a mean follow-up of 11.6 years, the average annual rate of HBsAg loss was 1.6%. Baseline HBsAg and HBV DNA levels were inversely associated with subsequent HBsAg loss. When compared to patients who had HBsAg levels >1000 IU/mL, the rates of HBsAg loss were significantly higher in patients with HBsAg levels of 100-999, 10-99, and <10 IU/mL, with hazard ratios of 2.5 (95% confidence interval [CI], 1.6-4.0), 2.8 (95% CI, 1.6-5.0), and 13.2 (95% CI, 8.1-21.5), respectively. Multivariate analysis showed that HBsAg level, but not HBV DNA, remained as an independent factor. The adjusted hazard ratio of HBsAg loss was 13.2 (95% CI, 7.8-22.1) for HBsAg level <10 versus ≥ 1000 IU/mL. When compared to HBV DNA level by receiver operating characteristic curve analysis, HBsAg level served as a better predictor of both 5-year and 10-year HBsAg loss., Conclusion: In HBeAg-negative patients with HBV genotype B or C infection who have HBV DNA level <2000 IU/mL, HBsAg level <10 IU/mL is the strongest predictor of HBsAg loss., (Copyright © 2011 American Association for the Study of Liver Diseases.)
- Published
- 2012
- Full Text
- View/download PDF
14. APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: more questions than answers.
- Author
-
Su TH, Kao JH, and Chen DS
- Subjects
- Hepatitis C, Chronic blood, Humans, Predictive Value of Tests, Antiviral Agents therapeutic use, Aspartate Aminotransferases blood, Hepatitis C, Chronic drug therapy, Interferons therapeutic use, Platelet Count
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.